Bliss GVS Pharma Limited
BLISSGVS · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹326.8.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- –ROE above 15%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✓Revenue growth > 10%30%
- ✓Earnings growing125%
- ✓Net margin ≥ 10%12.6%
- –Current ratio > 1.5
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 13.11
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Trading near its 52-week high.
- •Financially solid — Altman Z 13.11.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Earnings growing (125% YoY).
- •Revenue growing (30% YoY).
About Bliss GVS Pharma Limited
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, t
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.